Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer
- PMID: 35176150
- DOI: 10.1158/1078-0432.CCR-21-4592
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer
Abstract
The combination of chemotherapy and immune therapies still promises to synergize for prolonged tumor control. However, the quest for optimal combinations tailored for tumor histology remains ongoing. A recent study provides evidence on the feasibility of the trabectedin/durvalumab combination and reports on interesting preliminary efficacy. See related article by Toulmonde et al., p. 1765.
©2022 American Association for Cancer Research.
Comment in
-
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.Clin Cancer Res. 2022 May 2;28(9):1765-1772. doi: 10.1158/1078-0432.CCR-21-2258. Clin Cancer Res. 2022. PMID: 34965951
Comment on
-
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.Clin Cancer Res. 2022 May 2;28(9):1765-1772. doi: 10.1158/1078-0432.CCR-21-2258. Clin Cancer Res. 2022. PMID: 34965951
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical